We all know a split is coming. However why rush into it now. This company will have not one but two sources of revenue this year alone. I trust GC and the team to keep working the bugs out. I would hate to see a massive RS just to uplist then get hit by a delay. If we start a slow and steady stream of revenue it will show many investors that our products are not just a idea. Which strengthens the companies credibility. Patience and timing is definitely key here.
WD
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links